

Johannes F E Mann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3906023/publications.pdf>

Version: 2024-02-01

78
papers

14,473
citations

76294

40
h-index

62565

80
g-index

82
all docs

82
docs citations

82
times ranked

14297
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter regarding "œdiagnosis and treatment of arterial hypertension 2021" Kidney International, 2022, 101, 828-830.	2.6	1
2	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
3	Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial. BMJ Open, 2022, 12, e051907.	0.8	4
4	Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Frontiers in Pharmacology, 2022, 13, 786767.	1.6	2
5	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022, 65, 1085-1097.	2.9	28
6	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	4.3	30
7	Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney International, 2021, 99, 314-318.	2.6	14
8	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension, 2021, 39, 766-774.	0.3	9
9	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 2021, 99, 559-569.	2.6	169
10	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2058-2066.	2.2	33
11	Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. Current Cardiology Reports, 2021, 23, 132.	1.3	5
12	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 1270-1281.	2.0	41
13	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	2.6	65
14	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1 "7 randomised controlled trials. Lancet Diabetes and Endocrinology, 2020, 8, 880-893.	5.5	86
15	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
16	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. Diabetes, Obesity and Metabolism, 2020, 22, 2077-2088.	2.2	10
17	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	2.2	32
18	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care, 2020, 43, 1803-1812.	4.3	44

#	ARTICLE	IF	CITATIONS
19	SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
20	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1027-1036.	2.6	60
21	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. <i>BMC Nephrology</i> , 2019, 20, 81.	0.8	6
22	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	1.0	47
23	Blood HER2 and Uromodulin as Causal Mediators of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1326-1335.	3.0	21
24	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 2908-2918.	1.6	88
25	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140) mmHg in clinical trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	1.0	92
26	Long-term treatment with biosimilar epoetin- α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. <i>Clinical Nephrology</i> , 2018, 89, 1-9.	0.4	7
27	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	6.3	263
28	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	13.9	903
29	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2195-2198.	13.9	31
30	One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1918-1926.	0.4	21
31	Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. <i>Lancet, The</i> , 2016, 388, 465-475.	6.3	381
32	Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 29-40.	2.1	46
33	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.	13.9	5,070
34	Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. <i>Kidney International</i> , 2016, 89, 1380-1387.	2.6	27
35	Diet and Major Renal Outcomes: A Prospective Cohort Study. <i>The NIH-AARP Diet and Health Study</i> , 2016, 26, 288-298.		68
36	Dual renin-angiotensin system blockade and outcome benefits in hypertension. <i>Current Opinion in Cardiology</i> , 2015, 30, 373-377.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv1-iv5.	0.4	9
38	Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv76-iv85.	0.4	31
39	Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv26-iv34.	0.4	41
40	Risk Prediction for Early CKD in Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1371-1379.	2.2	97
41	Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1037-1046.	0.4	109
42	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , 2015, 87, 784-791.	2.6	86
43	Sodium Intake and Renal Outcomes: A Systematic Review. <i>American Journal of Hypertension</i> , 2014, 27, 1277-1284.	1.0	66
44	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. <i>Internal and Emergency Medicine</i> , 2013, 8, 389-399.	1.0	9
45	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.	1.2	182
46	Dual RAS blockade—unresolved controversy?. <i>Nature Reviews Nephrology</i> , 2013, 9, 640-640.	4.1	1
47	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes. <i>Journal of Hypertension</i> , 2013, 31, 414-421.	0.3	72
48	Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk. <i>Annals of Internal Medicine</i> , 2011, 154, 310.	2.0	74
49	Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1353-1364.	3.0	234
50	What's new in hypertension 2010?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 50-55.	0.4	4
51	Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk. <i>Circulation</i> , 2011, 123, 1098-1107.	1.6	135
52	Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. <i>Clinical Nephrology</i> , 2011, 76, 9-15.	0.4	16
53	Avosentan for Overt Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 527-535.	3.0	428
54	What's new in hypertension 2009?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 37-41.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Effect of Telmisartan on Renal Outcomes. <i>Annals of Internal Medicine</i> , 2009, 151, 1.	2.0	163
56	The COOPERATE trial: a letter of concern. <i>Lancet</i> , The, 2008, 371, 1575-1576.	6.3	89
57	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) Tj ETQq1 1 0.784314 rgBT /Overlo 6.3 1,442	6.3	1,442
58	What's new in hypertension 2008?. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 38-42.	0.4	5
59	Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. <i>Annals of Internal Medicine</i> , 2008, 148, 30.	2.0	626
60	Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 645-653.	0.4	82
61	What's new in hypertension 2007?. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 466-470.	0.4	1
62	Chronic Kidney Disease. <i>Circulation</i> , 2007, 116, 85-97.	1.6	1,278
63	Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. <i>Clinical Nephrology</i> , 2007, 67, 140-148.	0.4	27
64	Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>American Journal of Kidney Diseases</i> , 2006, 48, 889-896.	2.1	25
65	Clinic versus home blood-pressure measurements as a predictor of outcomes in chronic kidney disease. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 474-475.	2.0	1
66	What's new in hypertension?. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 47-52.	0.4	1
67	Optimal Treatment of Renal Anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, iii25-iii32.	0.4	25
68	Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. <i>Presse Medicale</i> , 2005, 34, 1303-1308.	0.8	18
69	How Does Minor Renal Dysfunction Influence Cardiovascular Risk and the Management of Cardiovascular Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 517-523.	3.0	55
70	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. <i>Kidney International</i> , 2004, 65, 1375-1380.	2.6	102
71	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. <i>Kidney International</i> , 2004, 66, S59-S62.	2.6	70
72	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. <i>American Journal of Kidney Diseases</i> , 2003, 42, 936-942.	2.1	75

#	ARTICLE	IF	CITATIONS
73	Cardiovascular risk in patients with mild renal insufficiency. <i>Kidney International</i> , 2003, 63, S192-S196.	2.6	61
74	Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 641-647.	3.0	130
75	Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy. <i>Diabetes Care</i> , 2002, 25, 1919-1927.	4.3	349
76	Cardiovascular Risk in Patients with Early Renal Insufficiency. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 157-162.	1.0	29
77	ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1100-1108.	3.0	110
78	Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 105-115.	3.0	206